Related Experiment Video
Updated: May 14, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
Serum HMGB1 and Alcohol-Related Liver Disease
Iwona Popiolek1,2, Piotr Hydzik1,2, Krzysztof Ciszowski1,2
1Department of Toxicology and Environmental Diseases, Jagiellonian University Medical College, Botaniczna 3, 31-503 Kraków, Poland.
Insights
Circulating High-mobility group box 1 (HMGB1) is detectable in some patients with alcohol-related liver disease (ALD) and indicates greater disease severity. This potential biomarker is more frequent in ALD patients than controls.
Area of Science:
- Hepatology
- Biomarker Discovery
- Immunology
Background:
- Alcohol-related liver disease (ALD) lacks validated biomarkers for disease activity and severity.
- High-mobility group box 1 (HMGB1), a damage-associated molecular pattern, is implicated in ALD pathogenesis.
Purpose of the Study:
- To evaluate the detectability of circulating HMGB1 in patients with ALD during active alcohol consumption.
- To examine the clinical associations of detectable HMGB1 in ALD patients.
Main Methods:
- Observational study of hospitalized adults with ongoing ethanol use and healthy controls.
- Serum HMGB1 measured by ELISA; clinical features and severity scores (MELD, MELD-Na, CLIF-C AD) recorded.
Main Results:
- HMGB1 was detectable in 47% of ALD patients vs. 11% of controls.
- Detectable HMGB1 correlated with higher bilirubin, creatinine, white cell count, and greater MELD, MELD-Na, and CLIF-C AD scores.
- No significant differences in mortality or readmission rates based on HMGB1 status.
Conclusions:
- Detectable circulating HMGB1 is present in a subset of ALD patients.
- HMGB1 detectability is associated with increased liver disease severity in ALD.
Abstract:
Background/Objectives: Alcohol-related liver disease (ALD) lacks widely adopted biomarkers that reflect disease activity and severity. High-mobility group box 1 (HMGB1), a damage-associated molecular pattern, has been implicated in ALD pathogenesis. We evaluated the detectability of circulating HMGB1 in patients with ALD during active alcohol use and examined clinical associations. Methods: In this observational study, we enrolled hospitalized adults with ongoing ethanol use between 1 November 2023, and 31 December 2024. Controls had no history of excessive alcohol consumption and normal liver biochemistry. Clinical features, laboratory tests, and severity scores (including MELD, MELD-Na, and CLIF-C AD) were recorded. Serum HMGB1 was measured by ELISA; values ≥ 0.08 ng/mL were considered detectable. Results: The cohort included 68 participants (58 with ALD and 10 controls); 29 patients had cirrhosis. HMGB1 was detectable in 32 measurements (42%), with a median concentration of 4.6 ng/mL (IQR, 0.78-10.6; range, 0.08-140.6). Detectable HMGB1 was more frequent in ALD than in controls (47% vs. 11%). Compared with HMGB1-negative patients, HMGB1-positive patients had higher total bilirubin and creatinine levels, prolonged activated partial thromboplastin time, higher white cell counts, and lower serum sodium. Liver enzyme activities and INR did not differ meaningfully by HMGB1 status. MELD, MELD-Na, and CLIF-C AD scores were higher in HMGB1-positive patients. Admission ethanol levels were higher in HMGB1-negative patients. Mortality and readmission did not differ by HMGB1 status. Conclusions: Detectable circulating HMGB1 is present in a subset of patients with ALD and is associated with greater liver disease severity.
Related Concept Videos
Cirrhosis I: Introduction
Hepatitis
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatic Encephalopathy
Jaundice
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
